Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017


June 1, 2011
65 Pages - SKU: GBDT6505603
License type:
Table of Contents Search inside this report Related Reports Detailed Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Acute SCI Therapeutics: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Pattern
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 Acute SCI Therapeutics: Market Characterization
3.1 Overview
3.2 Acute SCI Therapeutics Market Size (2005-2010) - Global
3.3 Acute SCI Therapeutics Market Forecast (2010-2017) - Global
3.4 Acute SCI Therapeutics Market Size (2005-2010) - The US
3.5 Acute SCI Therapeutics Market Forecast (2010-2017) - The US
3.6 Acute SCI Therapeutics Market Size (2005-2010) - France
3.7 Acute SCI Therapeutics Market Forecast (2010-2017) - France
3.8 Acute SCI Therapeutics Market Size (2005-2010) - Germany
3.9 Acute SCI Therapeutics Market Forecast (2010-2017) - Germany
3.10 Acute SCI Therapeutics Market Size (2005-2010) - Italy
3.11 Acute SCI Therapeutics Market Forecast (2010-2017) - Italy
3.12 Acute SCI Therapeutics Market Size (2005-2010) - Spain
3.13 Acute SCI Therapeutics Market Forecast (2010-2017) - Spain
3.14 Acute SCI Therapeutics Market Size (2005-2010) - The UK
3.15 Acute SCI Therapeutics Market Forecast (2010-2017) - The UK
3.16 Acute SCI Therapeutics Market Size (2005-2010) - Japan
3.17 Acute SCI Therapeutics Market Forecast (2010-2017) - Japan
3.18 Drivers and Barriers for the Acute SCI Therapeutics Market
3.18.1 Drivers for the Acute SCI Therapeutics Market
3.18.2 Barriers for Acute SCI Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.19.1 Opportunity and Unmet Need in the Acute SCI Market
3.20 Key Takeaway
4 Acute SCI Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Acute SCI Therapeutics
4.3.1 Medrol
4.4 Key Takeaway
5 Acute SCI Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Acute SCI Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Acute SCI Therapeutics - Phase III Pipeline
5.3.2 Acute SCI Therapeutics -Phase II Pipeline
5.3.3 Acute SCI Therapeutics -Phase I Pipeline
5.3.4 Acute SCI Therapeutics - Preclinical Phase
5.3.5 Acute SCI Therapeutics - Discovery Pipeline
5.4 Technology Trends Analytic Framework
5.5 Acute SCI Therapeutics Market - Pipeline by Mechanism of Action
5.6 Acute SCI Therapeutics - Promising Drugs under Clinical Development
5.7 Molecule Profiling for Promising Drugs Under Clinical Development
5.7.1 Lyrica
5.7.2 ProCord
5.8 Key Takeaway
6 Acute SCI Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Top 10 Companies Participating in Therapeutics Clinical Trials
6.5 Prominent Sponsors
7 Acute SCI Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition
8 Acute SCI Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Pfizer
8.2.2 Proneuron Biotechnologies
9 Acute SCI Therapeuctics: Licensing and Partnership Deals
10 Acute SCI Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Effects of SCI by Location
Table 2: Spinal Injury Impairment Scale
Table 3: Acute SCI Therapeutics Market, Global, Revenue, ($m), 2005-2010
Table 4: Acute SCI Therapeutics Market, Global, Forecast ($m), 2010-2017
Table 5: Acute SCI Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 6: Acute SCI Therapeutics Market, The US, Forecast ($m), 2010-2017
Table 7: Acute SCI Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: Acute SCI Therapeutics Market, France, Forecasts ($m), 2010-2017
Table 9: Acute SCI Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: Acute SCI Therapeutics Market, Germany, Forecast ($m), 2010-2017
Table 11: Acute SCI Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: Acute SCI Therapeutics Market, Italy, Forecast ($m), 2010-2017
Table 13: Acute SCI Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: Acute SCI Therapeutics Market, Spain, Forecast ($m), 2010-2017
Table 15: Acute SCI Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 16: Acute SCI Therapeutics Market, The UK, Forecast ($m), 2010-2017
Table 17: Acute SCI Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: Acute SCI Therapeutics Market, Japan, Forecast ($m), 2010-2017
Table 19: Acute SCI Therapeutics - Phase III Clinical Pipeline, 2011
Table 20: Acute SCI Therapeutics - Phase II Clinical Pipeline, 2011
Table 21: Acute SCI Therapeutics - Phase I Clinical Pipeline, 2011
Table 22: Acute SCI Therapeutics - Preclinical Pipeline, 2011
Table 23: Acute SCI Therapeutics - Discovery Pipeline, 2011
Table 24: Acute SCI Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 25: Acute SCI Therapeutics Market, Clinical Trials by Country, 2011
Table 26: Acute SCI Therapeutics Market, Clinical Trials by Phase, 2011
Table 27: Acute SCI Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 28: Acute SCI Therapeutics Market, Clinical Trials by Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Acute SCI Therapeutics Market - Clinical Trials by Overall Sponsors, 2011
Table 30: Acute SCI Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Table 31: Pfizer, CNS Pipeline, As on February 28, 2011
Table 32: Pfizer, SCI Pipeline, February 28, 2011
Table 33: Pfizer, Deals, 2009-2010
Table 34: NeuroHealing Pharmaceuticals - CNS Pipeline Products, 2011
Table 35: SCI Therapeutics Market, Global, Deals, 2007-2008
1.2 List of Figures
Figure 1: Spinal Cord After Injury
Figure 2: Acute SCI Therapeutics Market - SCI Causes
Figure 3: Effects of SCIs
Figure 4: Referral Pathway for Acute SCI
Figure 5: Acute SCI Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 6: Acute SCI Therapeutics Market, Global, Forecast ($m), 2010-2017
Figure 7: Acute SCI Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 8: Acute SCI Therapeutics Market, The US, Forecast ($m), 2010-2017
Figure 9: Acute SCI Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 10: Acute SCI Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 11: Acute SCI Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 12: Acute SCI Therapeutics Market, Germany, Forecast ($m), 2010-2017
Figure 13: Acute SCI Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 14: Acute SCI Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 15: Acute SCI Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 16: Acute SCI Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 17: Acute SCI Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 18: Acute SCI Therapeutics Market, The UK, Forecast ($m), 2010-2017
Figure 19: Acute SCI Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 20: Acute SCI Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 21: Opportunity and Unmet Need in the Acute SCI Therapeutics Market, 2010
Figure 22: Strategic Competitor Assessment of the Marketed Products for Acute SCIs, 2011
Figure 23: Acute SCI Therapeutics Pipeline by Phase of Development, 2011
Figure 24: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline, 2011
Figure 25: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline- Description, 2011
Figure 26: Acute SCI Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 27: Acute SCI Therapeutics Market, Clinical Trials by Country, 2011
Figure 28: Acute SCI Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 29: Acute SCI Therapeutics Market - Clinical Trials by Trial Status, 2011
Figure 30: Acute SCI Therapeutics Market - Clinical Trials by Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 31: Acute SCI Therapeutics Market - Clinical Trials by Overall Sponsors, 2011
Figure 32: Acute SCI Therapeutics Market - Clinical Trials by Prominent Sponsors, 2011
Figure 33: Acute SCI Therapeutics Market, Drivers and Barriers, 2011
Figure 34: Implications for Future Market Competition in the Acute SCI Therapeutics Market, 2011
Figure 35: Acute SCI Therapeutics Market - Clinical Pipeline by Company, 2011
Figure 36: GlobalData Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Orthopedics Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!